What is Vidac Pharma?
Vidac Pharma is a clinical-stage biopharmaceutical firm dedicated to pioneering first-in-class oncologic and onco-dermatologic therapies. The company's core innovation lies in a novel technology designed to correct a universal characteristic found in all cancer cells. This breakthrough holds the promise of introducing a fundamentally new modality for cancer treatment, potentially becoming an integral component of future oncology combination therapies.
How much funding has Vidac Pharma raised?
Vidac Pharma has raised a total of $9.6M across 2 funding rounds:
Series A
$9M
Other Financing Round
$645K
Series A (2016): $9M with participation from Israel Biotech Fund
Other Financing Round (2024): $645K, investors not publicly disclosed
Key Investors in Vidac Pharma
Israel Biotech Fund
Israel Biotech Fund I LP is a company that operates in the Investment Banking industry. It employs 5to9 people and has 500Kto1M of revenue. The company is headquartered in Rehovot, Central District, Israel.
What's next for Vidac Pharma?
The substantial enterprise-level funding and recent strategic investment signal a critical inflection point for Vidac Pharma. This capital infusion is expected to accelerate the company's clinical development pipeline, potentially enabling further validation of its unique cancer cell targeting technology. Strategic partnerships and expanded research initiatives are likely next steps as Vidac Pharma aims to translate its promising scientific platform into impactful treatments for patients battling cancer.
See full Vidac Pharma company page
